India joins the Global Antimicrobial Resistance R&D Hub
Why in News?
The Department of Biotechnology under the Ministry of Science and Technology has announced that India has now become a member of the Global Anti-Microbial Resistance (AMR) Research and Development (R&D) Hub.
What is Global AMR and R&D?
- The programme was launched in May 2018 on the sidelines of 71st session of the World Health Assembly held at Geneva, Switzerland. This was in response to the call of G20 member nations in 2017.
- The hub supports global priority setting and evidence-based decision making on the allocation of the resources for antimicrobial research and development through the identification of gaps, overlaps and potential for cross-sectoral collaboration and leveraging in AMR R&D.
- The collaboration works to address the challenges and improve coordination in the global antimicrobial resistance research and development. The issue of requires global action with active participation from all regions of the world.
India’s Role at the Hub
India will be one of the board members of the Global Antimicrobial Resistance R&D hub. India aims to work with all the hub partners to boost their existing capabilities, resources and collectively focus on new R&D intervention to address infections that are drug resistant.
It refers to a microbe’s ability to resist the effects of drugs that could once treat it successfully. The emergence and spread of AMR is at present unchecked around the world. The Resistant microbes turn out to be very difficult to treat. They require alternative medication or higher doses of antimicrobials which can be more expensive as well as toxic. The microbes resistant to multiple antimicrobials are called multi-drug resistant (MDR).
The thought process of India goes that it is feasible to explore the menace of antimicrobial resistance through a collaborative effort which should be complimented by long term commitments from all stakeholders.